George Georges

1.2k total citations
75 papers, 772 citations indexed

About

George Georges is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, George Georges has authored 75 papers receiving a total of 772 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Physiology, 48 papers in Pulmonary and Respiratory Medicine and 25 papers in Immunology and Allergy. Recurrent topics in George Georges's work include Asthma and respiratory diseases (52 papers), Inhalation and Respiratory Drug Delivery (30 papers) and Respiratory and Cough-Related Research (25 papers). George Georges is often cited by papers focused on Asthma and respiratory diseases (52 papers), Inhalation and Respiratory Drug Delivery (30 papers) and Respiratory and Cough-Related Research (25 papers). George Georges collaborates with scholars based in United States, Italy and United Kingdom. George Georges's co-authors include Yuning Liao, Suzanne Meeves, Alberto Papi, Dave Singh, Paul H. Ratner, Giorgio Walter Canonica, J. Christian Virchow, Maxim Kots, Piotr Kuna and Leon Dupclay and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and CHEST Journal.

In The Last Decade

George Georges

69 papers receiving 739 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
George Georges United States	16	601	409	340	88	69	75	772
Robert Berkowitz United States	14	498 0.8×	287 0.7×	329 1.0×	95 1.1×	58 0.8×	24	684
Cláudia Chaves Loureiro Portugal	12	333 0.6×	175 0.4×	218 0.6×	22 0.3×	53 0.8×	43	503
E. Philpot United States	20	936 1.6×	336 0.8×	973 2.9×	281 3.2×	134 1.9×	51	1.1k
T.F. Reiss United States	6	932 1.6×	777 1.9×	328 1.0×	8 0.1×	23 0.3×	10	1.0k
I Wahedna United Kingdom	8	312 0.5×	230 0.6×	44 0.1×	9 0.1×	5 0.1×	13	432
Hanne H. Villesen Denmark	9	365 0.6×	112 0.3×	297 0.9×	11 0.1×	143 2.1×	14	470
Anna von Bülow Denmark	14	460 0.8×	309 0.8×	99 0.3×	6 0.1×	35 0.5×	36	551
A Knight Canada	13	305 0.5×	231 0.6×	162 0.5×	9 0.1×	73 1.1×	17	460
M.P. Derde Belgium	8	120 0.2×	91 0.2×	77 0.2×	6 0.1×	19 0.3×	12	295
Kobi Sade Israel	11	144 0.2×	76 0.2×	150 0.4×	3 0.0×	80 1.2×	18	359

Countries citing papers authored by George Georges

Since Specialization

Citations

This map shows the geographic impact of George Georges's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Georges with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Georges more than expected).

Fields of papers citing papers by George Georges

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George Georges. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Georges. The network helps show where George Georges may publish in the future.

Co-authorship network of co-authors of George Georges

This figure shows the co-authorship network connecting the top 25 collaborators of George Georges. A scholar is included among the top collaborators of George Georges based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George Georges. George Georges is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brusselle, Guy, Alberto Papi, J. Christian Virchow, et al.. (2025). Achieving asthma remission with extrafine beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB) pMDI in adults with moderate-to-severe asthma: A post-hoc analysis of the TRIMARAN and TRIGGER Studies. Journal of Allergy and Clinical Immunology. 155(2). AB235–AB235. 1 indexed citations

Patterson, P. Daniel, Cassie J. Hilditch, Matthew D. Weaver, et al.. (2023). Are Short Duration Naps Better than Long Duration Naps for Mitigating Sleep Inertia? Brief Report of a Randomized Crossover Trial of Simulated Night Shift Work. Prehospital Emergency Care. 27(6). 807–814. 4 indexed citations

Skloot, Gwen, Alessandro Guasconi, George Georges, et al.. (2023). The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN). Respiratory Research. 24(1). 244–244. 1 indexed citations

Geßner, Christian, et al.. (2022). Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany – The TriOptimize Study. International Journal of COPD. Volume 17. 3019–3031. 11 indexed citations

Price, David, William Henley, José Eduardo Delfini Cançado, et al.. (2022). Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone. SHILAP Revista de lepidopterología. 6 indexed citations

Usmani, Omar S., et al.. (2022). Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 35(4). 179–185. 19 indexed citations

Cella, Massimo, et al.. (2021). Ethnic Sensitivity Study of the Extrafine, Single-Inhaler, Triple Therapy Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide Pressurized Metered Dose Inhaler in Japanese and Caucasian Healthy Individuals: A Randomized, Double-Blind, Single-Dose Crossover Study. Clinical Therapeutics. 43(11). 1934–1947.e4. 6 indexed citations

Zheng, Jinping, S. Baldi, Li Zhao, et al.. (2021). Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial. Respiratory Research. 22(1). 90–90. 11 indexed citations

Scichilone, Nicola, et al.. (2020). Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations. SHILAP Revista de lepidopterología. 2 indexed citations

10.

Usmani, Omar S., et al.. (2020). <p>Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations</p>. International Journal of COPD. Volume 15. 2433–2440. 30 indexed citations

11.

Usmani, Omar S., et al.. (2020). Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An In Silico Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 34(3). 204–211. 20 indexed citations

12.

Georges, George, et al.. (2014). Effect of intranasal triamcinolone acetonide on basal hypothalamic‐pituitary‐adrenal axis function in children with allergic rhinitis. Allergy and Asthma Proceedings. 35(2). 163–170. 5 indexed citations

13.

Segall, Nathan, et al.. (2010). Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. Annals of Allergy Asthma & Immunology. 104(3). 259–267. 21 indexed citations

14.

Weinstein, Steven F., Paul Y. Qaqundah, George Georges, & Anjuli Nayak. (2009). Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Annals of Allergy Asthma & Immunology. 102(4). 339–347. 15 indexed citations

15.

Weber, Richard W., et al.. (2006). Safety and clinical relief over 1 year with triamcinolone acetonide hydrofluoroalkane-134a nasal aerosol in patients with perennial allergic rhinitis. Allergy and Asthma Proceedings. 27(3). 243–247. 5 indexed citations

16.

Kaplan, Allen P., Sheldon L. Spector, Suzanne Meeves, et al.. (2005). Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Annals of Allergy Asthma & Immunology. 94(6). 662–669. 44 indexed citations

17.

Liao, Yuning, et al.. (2004). Triamcinolone acetonide aqueous nasal spray improves nocturnal rhinitis-related quality of life in patients treated in a primary care setting: the Quality of Sleep in Allergic Rhinitis study. Annals of Allergy Asthma & Immunology. 92(2). 255–261. 29 indexed citations

18.

Kaliner, Michael, Martha V. White, Athena Economides, et al.. (2003). Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression. Annals of Allergy Asthma & Immunology. 90(6). 629–634. 16 indexed citations

19.

Gross, Gary N., et al.. (2002). Comparative efficacy, safety, and effect on quality of life of triamcinolone acetonide and fluticasone propionate aqueous nasal sprays in patients with fall seasonal allergic rhinitis. Annals of Allergy Asthma & Immunology. 89(1). 56–62. 32 indexed citations

20.

Ratner, Paul H., et al.. (2000). Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 105(6). 1101–1107. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact